Compare TMDE & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMDE | ICU |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 15.9M |
| IPO Year | 2025 | N/A |
| Metric | TMDE | ICU |
|---|---|---|
| Price | $0.74 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.1K | ★ 2.2M |
| Earning Date | 09-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $607,422,733.00 | $881,000.00 |
| Revenue This Year | N/A | $691.85 |
| Revenue Next Year | N/A | $64.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1195.59 |
| 52 Week Low | $0.60 | $0.29 |
| 52 Week High | $6.27 | $3.07 |
| Indicator | TMDE | ICU |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.22 |
| Support Level | N/A | $0.30 |
| Resistance Level | N/A | $0.35 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 65.94 |
TMD Energy Ltd is engaged in marine fuel bunkering services specializing in the supply and marketing of marine gas oil and marine fuel oil (including high sulfur fuel oil, low sulfur fuel oil and very low sulfur fuel oil), to ships and vessels at sea. It is also involved in the provision of ship management services for in-house and external vessels, as well as vessel chartering. It is currently operating with a fleet of nearly 15 bunkering vessels ranging from 540 dwt to 7,820 dwt, of which nearly nine (9) are double bottom and double hull vessels with an average cargo-carrying capacity of approximately 4,200 dwt each.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.